Stereotactic Body Radiotherapy for the Management of Early-Stage Non-Small-Cell Lung Cancer: A Clinical Overview

被引：27
作者：
Buchberger, David S. [1 ]
Videtic, Gregory M. M. [1 ,2 ]
机构：
[1] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, Cleveland, OH USA
[2] Cleveland Clin, Taussig Canc Inst, Dept Radiat Oncol, 9500 Euclid Ave, Cleveland, OH 44195 USA
来源：
JCO ONCOLOGY PRACTICE | 2023年 / 19卷 / 05期
关键词：
QUALITY-OF-LIFE; RADIATION-THERAPY; ABLATIVE RADIOTHERAPY; LOCAL RECURRENCE; DOSE IRRADIATION; RANDOMIZED-TRIAL; SBRT; CARCINOMA; TUMORS; RESECTION;
D O I：
10.1200/OP.22.00475
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：239 / +
页数：12
相关论文
共 92 条
[1]   Systematic review of case reports on the abscopal effect [J].
Abuodeh, Yazan ;
Venkat, Puja ;
Kim, Sungjune .
CURRENT PROBLEMS IN CANCER, 2016, 40 (01) :25-37
[2]   Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life: Benefit for Patients With Low Initial Scores (STRIPE Trial) [J].
Adebahr, Sonja ;
Hechtner, Marlene ;
Schraeder, Nele ;
Schimek-Jasch, Tanja ;
Kaier, Klaus ;
Duncker-Rohr, Viola ;
Gkika, Eleni ;
Momm, Felix ;
Gaertner, Jan ;
Becker, Gerhild ;
Grosu, Anca-Ligia ;
Nestle, Ursula .
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (03) :408-419
[3]  
[Anonymous], A randomized phase III trial of intravesical BCG versus intravesical docetaxel and gemcitabine treatment in BCG naive high grade non-muscle invasive bladder cancer (BRIDGE)
[4]  
[Anonymous], SUBL RES STER ABL RA
[5]  
[Anonymous], Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients / Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation (PACIFIC-4)
[6]  
[Anonymous], Veterans Affairs Lung Cancer Surgery or Stereotactic Radiotherapy (VALOR)
[7]  
[Anonymous], Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) with or Without Pembrolizumab (MK-3475) in Adults with Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
[8]  
[Anonymous], 2022, Cancer: Key facts
[9]   Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].
Antonia, S. J. ;
Villegas, A. ;
Daniel, D. ;
Vicente, D. ;
Murakami, S. ;
Hui, R. ;
Yokoi, T. ;
Chiappori, A. ;
Lee, K. H. ;
de Wit, M. ;
Cho, B. C. ;
Bourhaba, M. ;
Quantin, X. ;
Tokito, T. ;
Mekhail, T. ;
Planchard, D. ;
Kim, Y. -C. ;
Karapetis, C. S. ;
Hiret, S. ;
Ostoros, G. ;
Kubota, K. ;
Gray, J. E. ;
Paz-Ares, L. ;
de Castro Carpeno, J. ;
Wadsworth, C. ;
Melillo, G. ;
Jiang, H. ;
Huang, Y. ;
Dennis, P. A. ;
Ozguroglu, M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929
[10]   Long-term Clinical Outcomes and Safety Profile of SBRT for Centrally Located NSCLC [J].
Arnett, Andrea L. H. ;
Mou, Benjamin ;
Owen, Dawn ;
Park, Sean S. ;
Nelson, Katy ;
Hallemeier, Christopher L. ;
Sio, Terence ;
Garces, Yolanda, I ;
Olivier, Kenneth R. ;
Merrell, Kenneth W. .
ADVANCES IN RADIATION ONCOLOGY, 2019, 4 (02) :422-428
12345678910